Equine PIVKA-Ⅱ antibody and antigen (recombinant protein)
Diagnostic anti-Equine PIVKA-Ⅱ antibodies pairs and antigen for animal health (animal Equine/Horse hepatocellular carcinoma) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Equine disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-PIVKA-Ⅱ-Ag01 | Equine PIVKA-Ⅱ | $3090.00 |
GMP-EQU-PIVKA-Ⅱ-Ab01 | Anti-Equine PIVKA-Ⅱ mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-PIVKA-Ⅱ-Ab02 | Anti-Equine PIVKA-Ⅱ mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-PIVKA-Ⅱ-Ab03 | Anti-Equine PIVKA-Ⅱ human monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-PIVKA-Ⅱ-Ab04 | Anti-Equine PIVKA-Ⅱ human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-EQU-PIVKA-Ⅱ-Ag01 |
Product Name | Equine PIVKA-Ⅱ |
Target/Biomarker | Equine PIVKA-Ⅱ |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine PIVKA-Ⅱ antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in PIVKA-Ⅱ level test of animal Equine/Horse with hepatocellular carcinoma. |
Tag | His | Reconized/Reactive Specics | Equine PIVKA-Ⅱ |
Product description | Recombinant Equine PIVKA-Ⅱ protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-PIVKA-Ⅱ-Ab01,GMP-EQU-PIVKA-Ⅱ-Ab02 |
Target/Biomarker | Equine PIVKA-Ⅱ |
Product Name | Anti-Equine PIVKA-Ⅱ mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine PIVKA-Ⅱ antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine PIVKA-Ⅱ antibodies in Equine PIVKA-Ⅱ level test of animal Equine/Horse with hepatocellular carcinoma. |
Product description | Anti-Equine PIVKA-Ⅱ mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine PIVKA-Ⅱ antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-PIVKA-Ⅱ-Ab03,GMP-EQU-PIVKA-Ⅱ-Ab04 |
Target/Biomarker | Equine PIVKA-Ⅱ |
Product Name | Anti-Equine PIVKA-Ⅱ human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Equine PIVKA-Ⅱ antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine PIVKA-Ⅱ antibodies in Equine PIVKA-Ⅱ level test of animal Equine/Horse with hepatocellular carcinoma. |
Product description | Anti-Equine PIVKA-Ⅱ mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
Equine PIVKA-Ⅱ, a captivating biomarker, takes on a pivotal role in the realm of equine health. Unique to horses, the significance of this biomarker lies in its association with coagulation abnormalities and Vitamin K-dependent clotting factors. Equine PIVKA-Ⅱ serves as a marker that reflects the intricate relationship between hemostasis, liver function, and the synthesis of clotting factors.
The presence of Equine PIVKA-Ⅱ is intrinsically linked to the activation of coagulation factors, especially those that rely on Vitamin K. When Vitamin K metabolism faces challenges, the levels of Equine PIVKA-Ⅱ may rise, signifying the body's endeavor to maintain normal hemostasis despite compromised clotting factors. Additionally, alterations in Equine PIVKA-Ⅱ levels can indicate potential liver dysfunction, given the liver's central role in clotting factor and Vitamin K synthesis.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.